May 1, 2018
Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs is challenging, in large part because good predictive biomarkers have yet to be identified and validated.
Understanding the role biomarkers can play in this emerging treatment landscape has large implications, especially for companies seeking to launch new drugs and compete with the market leaders by positioning them in indications where they hopefully show higher response rates. Biomarkers are the best hope for streamlining trials in this way and to help secure favourable pricing.
The article was written by Dr Rachel Laing and Olivier Lesueur
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: